BAG3基因变异对扩张型与肥厚型心肌病的双向风险调控
C151R携带者死亡和心脏移植风险更低,且在TTN截短变异携带者中降低扩张型心肌病和心衰风险。
要点
- BAG3 C151R变异与扩张型心肌病风险降低(OR 0.85)和肥厚型心肌病风险升高(OR 1.59)相关。
- C151R携带者年龄相关死亡风险(HR 0.85)和心脏移植风险(HR 0.81)低于非携带者。
- 在TTN截短变异携带者中,C151R与扩张型心肌病(OR 0.42)和心衰(OR 0.27)风险降低相关。
核心结论
- BAG3 C151R是扩张型-肥厚型心肌病谱系的双向风险调控因子,也是TTN介导扩张型心肌病的重要遗传修饰变异。
研究设计与样本
- 全外显子组测序与电子健康记录关联分析BAG3编码变异与临床表型。
- 在BioVU、UK Biobank、MyCode和DCM Precision Medicine Study中进行重复验证。
主要发现
- C151R携带者较非携带者死亡年龄更晚(HR 0.85;95%CI 0.74-0.96;中位年龄携带者71.8岁 vs 非携带者70.3岁)且心脏移植风险更低(HR 0.81;95%CI 0.66-0.99;中位年龄携带者56.7岁 vs 非携带者55.6岁)。
- 在具有高心脏表达外显子TTN截短变异的个体(n=358)中,C151R与扩张型心肌病风险降低(OR 0.42;95%CI 0.24-0.74)和心衰风险降低(OR 0.27;95%CI 0.14-0.50)相关。
临床怎么用
- BAG3 C151R可作为扩张型心肌病外显不全的遗传修饰标志,辅助风险分层。
- 对TTN截短变异携带者,检测BAG3 C151R可能有助于识别扩张型心肌病和心衰风险更低的个体。
- C151R携带者预后较好,或可影响随访强度和移植评估时机。
局限性
- 研究为横断面设计,关联分析不能确立因果关系。
- 主要基于欧洲和非洲遗传 ancestry人群,其他人群外推性有限。
- 未明确BAG3 C151R影响表型的生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The genetic factors that modulate the reduced penetrance and variable expressivity of heritable dilated cardiomyopathy (DCM) are largely unknown. BAG3 genetic variants have been implicated in both DCM and hypertrophic cardiomyopathy (HCM), nominating BAG3 as a gene that harbors potential modifier variants in DCM. OBJECTIVE: To interrogate the clinical traits and diseases associated with BAG3 coding variation. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional study in the Penn Medicine BioBank (PMBB) enrolling patients of the University of Pennsylvania Health System's clinical practice sites from 2014 to 2023. Whole-exome sequencing (WES) was linked to electronic health record (EHR) data to associate BAG3 coding variants with EHR phenotypes. This was a health care population-based study including individuals of European and African genetic ancestry in the PMBB with WES linked to EHR phenotypes, with replication studies in BioVU, UK Biobank, MyCode, and DCM Precision Medicine Study. EXPOSURES: Carrier status for BAG3 coding variants. MAIN OUTCOMES AND MEASURES: Association of BAG3 coding variation with clinical diagnoses, echocardiographic traits, and longitudinal outcomes. RESULTS: In PMBB (n = 43 731; median [IQR] age, 65 [50-76] years; 21 907 female [50.1%]), among 30 324 European and 11 198 African individuals, the common C151R variant was associated with decreased risk for DCM (odds ratio [OR], 0.85; 95% CI, 0.78-0.92) and simultaneous increased risk for HCM (OR, 1.59; 95% CI, 1.25-2.02), which was confirmed in the replication cohorts. C151R carriers exhibited improved longitudinal outcomes compared with noncarriers as assessed by age at death (hazard ratio [HR], 0.85; 95% CI, 0.74-0.96; median [IQR] age, 71.8 [63.1-80.7] in carriers and 70.3 [61.6-79.2] in noncarriers) and heart transplant (HR, 0.81; 95% CI, 0.66-0.99; median [IQR] age, 56.7 [46.1-63.1] in carriers and 55.6 [45.2-62.9] in noncarriers). C151R was associated with reduced risk of DCM (OR, 0.42; 95% CI, 0.24-0.74) and heart failure (OR, 0.27; 95% CI, 0.14-0.50) among individuals harboring truncating TTN variants in exons with high cardiac expression (n = 358). CONCLUSIONS AND RELEVANCE: BAG3 C151R was identified as a bidirectional modulator of risk along the DCM-HCM spectrum, as well as an important genetic modifier variant in TTN-mediated DCM. This work expands on the understanding of the etiology and penetrance of DCM, suggesting that BAG3 C151R is an important genetic modifier variant contributing to the variable expressivity of DCM, warranting further exploration of its mechanisms and of genetic modifiers in DCM more broadly.
引用
- Park J, Levin MG, Zhang D, et al. Bidirectional Risk Modulator and Modifier Variant of Dilated and Hypertrophic Cardiomyopathy in BAG3. JAMA Cardiol. 2024. PMID: 39535783. doi:10.1001/jamacardio.2024.3547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。